je.st
news
Puma Biotechnology Updates Timeline For Filing New Drug Application
2014-12-03 07:07:08| drugdiscoveryonline News Articles
Puma Biotechnology, Inc., a development stage biopharmaceutical company, recently provided an update on the timeline for filing its New Drug Application (NDA) for the approval of PB272 (neratinib) in the extended adjuvant treatment of HER2-positive early stage breast cancer
Tags: application
updates
drug
filing
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||